An Open-label Randomized Phase 1 Study to Investigate the Pharmacokinetics and Pharmacodynamics of Subcutaneous and Intravenous Administrations of Golimumab to Subjects With Rheumatoid Arthritis.
Latest Information Update: 08 Nov 2021
At a glance
- Drugs Golimumab (Primary) ; Golimumab (Primary)
- Indications Rheumatoid arthritis
- Focus Pharmacokinetics
- Sponsors Centocor
- 12 Dec 2011 Results published in the Clinical Therapeutics.
- 27 May 2011 Status changed from not stated to completed as reported by ClinicalTrials.gov.
- 27 May 2011 New source identified and integrated (ClinicalTrials.gov: US National Institutes of Health).